Skip to main content
SpringerLink
Log in

Therapie von oxidativem Streß

  • Chapter
Neuro-Psychopharmaka Ein Therapie-Handbuch

  • 86 Accesses

Zusammenfassung

Die Annahme, daβ oxidativer Streβ im Rahmen der Ätiopathogenese der Alzheimer Krankheit (DAT) eine wichtige Rolle spielen könnte, wird heute als vergleichsweise gut abgesicherte Hypothese angesehen. Man knüpft dabei an überlegungen an, die im Zusammenhang mit natürlichen Alterungsvorgängen und anderen neurodegenerativen Krankheiten schon intensiv erörtert worden sind. Besonders bei der Parkinsonschen Krankheit oder der amyotrophen Lateralsklerose wird dem Modell des neuronalen Zellunterganges durch oxidativen Streβ erhebliche Bedeutung zugesprochen (Hal-Liwell 1992, Jenner 1994, Frölich und Riederer 1995).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Agnoli A, Martucci N, Fabbrini G, Buckley A, Fioravanti M (1990) Monoamine oxidase and dementia: treatment with an inhibitor of MAOB activity. Dementia 1: 109–114

    Google Scholar 

  • Agnoli A, Fabbrini G, Fioravanti M, Martucci N (1992) CBF and cognitive evaluation of Alzheimer type patients before and after IMAOB treatment: a pilot study. Eur Neuropharmacol 2: 31–35

    Article  CAS  Google Scholar 

  • Bell J, Beglan C, London E (1996) Interaction of ascorbic acid with the neurotoxic effects of NMDA and sodium nitroprusside. Life Sci 58: 367–371

    Article  PubMed  CAS  Google Scholar 

  • Bergamasco B, Scarzella L, La Commare P (1994) Idebenone, a new drug in the treatment of cognitive impairment in patients with senile dementia of the Alzheimer type. Funct Neurol 9: 161–168

    PubMed  CAS  Google Scholar 

  • Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P (1995) Interleukin-1 bete and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett 202: 17–20

    Article  PubMed  CAS  Google Scholar 

  • Bruno V, Battaglia G, Copani A, Sortino MA, Canonico PL, Nicoletti F (1994) Protective action of idebenone against excitotoxic degeneration in cultured cortical neurons. Neurosci Lett 178: 193–196

    Article  PubMed  CAS  Google Scholar 

  • Burke W, Ranno A, Roccaforte W, Wengel S, Bayer B, Willcockson N (1993a) L-deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary results. J Am Geriatr Soc 41: 367–370

    PubMed  CAS  Google Scholar 

  • Burke W, Roccaforte W, Wengel S, Bayer B, Ranno A, Willcockson N (1993b) L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 41: 1219–1225

    PubMed  CAS  Google Scholar 

  • Burns A, Marsh A, Bender D (1989) A trial of vitamin supplementation in senile dementia. Int J Ger Psychiat 4: 333–338

    Article  Google Scholar 

  • Burton G, Ingold K (1989) Vitamin E as an in vitro and vivo antioxidant. Ann NY Acad Sci 570: 7–21

    Article  PubMed  CAS  Google Scholar 

  • Butterfield DA (1996) Commentary: Alzheimer’s disease: a disorder of oxidative stress. Alzheimer’s Dis Rev 1: 68–70

    CAS  Google Scholar 

  • Campi N, Todeschini GP, Scarzella L (1990) Selegiline versus 1-acetylcarnitine in the treatment of Alzheimer-type dementia. Clin Ther 12: 306–314

    PubMed  CAS  Google Scholar 

  • Dickson DW (1996) Commentary: Glycoxidation in Alzheimer’s disease: a specific mechanism of early lesion pathogenesis? Alzheimer’s Dis Rev 1: 75–76

    CAS  Google Scholar 

  • Falsaperla A, Monici Preti PA, Oliani C (1990) Selegiline versus oxiracetam in patients with Alzheimer’s type dementia. Clin Ther 12: 376–384

    PubMed  CAS  Google Scholar 

  • Fahn S (1992) A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson’s disease. Ann Neurol 32: 128–132

    Article  Google Scholar 

  • Finali G, Piccirilli M, Oliani C, Piccinin GL (1991) L-deprenyl therapy improves verbal memory in amnestic Alzheimer patients. Clin Neuropharmacol 14: 523–536

    Article  PubMed  CAS  Google Scholar 

  • Finali G, Piccirilli M, Oliani C, Piccinin GL (1992) Alzheimer-type dementia and verbal memory performance: influence of selegiline therapy. Ital J Neurol Sci 13: 141–148

    Article  PubMed  CAS  Google Scholar 

  • Fischer P, Götz ME, Danielczyk W, Gsell W, Riederer P (1997) Blood transferrin and ferritin in Alzheimer’s disease. Life Sci 60: 2273–2278

    Article  PubMed  CAS  Google Scholar 

  • Frei B, England L, Ames B (1989) Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci 86: 6377–6381

    Article  PubMed  CAS  Google Scholar 

  • Frölich L, Riederer P (1995) Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment. Drug Res 45: 443–446

    Google Scholar 

  • Gerlach M, Riederer P, Youdim MBH (1995) Neuroprotective therapeutic strategies. Biochem Pharmacol 50: 1–16

    Article  PubMed  CAS  Google Scholar 

  • Gillis JC, Benfield P, Mctavish D (1994) Ide-benone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs and Aging 5: 133–152

    Article  PubMed  CAS  Google Scholar 

  • Goad DL, Davis CM, Liem P, Fuselier CC, McCormack JR, Olsen KM (1991) The use of selegiline in Alzheimer’s patients with behavior problems. J Clin Psychiat 52: 342–345

    CAS  Google Scholar 

  • Götz ME, Fischer P, Gsell W, Riederer P, Streifler M, Simanyi M, Müller F, Danielczyk W (1998) Platelet monoamine oxidase B activity in dementia: a 4 year follow up. Dem Geriatr Cogn Disord 9: 74–77

    Article  Google Scholar 

  • Gsell W, Conrad R, Hickethier M, Sofic E, Frölich L, Wichart I, Jellinger K, Moll G, Ransmeyr G, Beckmann H, Riederer P (1995) Decreased catalase activity in brains of patients with dementia of Alzheimer type. J Neurochem 64: 1216–1223

    Article  PubMed  CAS  Google Scholar 

  • Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59: 1609–1623

    Article  PubMed  CAS  Google Scholar 

  • Hofferberth B (1994) The efficacy of Egb 761 in patients with senile dementia of the Alzheimer type, a double blind, placebo-controlled study on different levels of investigation. Hum Psychopharmacol 9: 215–222

    Article  Google Scholar 

  • Hoyer S (1997) Biochemie des alternden Hirnes. In: Rösler M, Retz W, Thome J (Hrsg) Die Alzheimer Krankheit. Beltz, Deutscher Studien Verlag, Weinheim

    Google Scholar 

  • Ihl R, Perisic I, Maurer K, Dierks T (1989) Effect of 3 months treatment with tenilsetam in patients suffering from dementia of Alzheimer type (DAT). J Neural Transm [PD-Sect] 1: 84–85

    Article  Google Scholar 

  • Jenner P (1994) Oxidative damage in neurodegenerative disease. Lancet 344: 796–798

    Article  PubMed  CAS  Google Scholar 

  • Kanowski S, Herrmann WM, Staphan K, Wierich W, Hörr R (1996) Proof of efficacy of the Ginkgo biloba special extract Egb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multiinfarct dementia. Pharmacopsychiatry 29: 47–56

    Article  PubMed  CAS  Google Scholar 

  • Koutsilieri E, O’Callaghan JF, Chen TS, Riederer P, Rausch WD (1994) Selegiline enhances survival and neurite outgrowth of MPP+-treated dopaminergic neurons. Eur J Pharmacol 269: R3–R4

    Article  PubMed  CAS  Google Scholar 

  • Lawlor B, Aisen P, Green C, Fine E, Schmeidler J (1997) Selegiline in the treatment of behavioural disturbance in Alzheimer’s disease. Int J Ger Psychiat 12: 319–322

    Article  CAS  Google Scholar 

  • Mangoni A, Grassi MP, Frattola L, Piolti R, Bassi S, Motta A, Marcone A, Smirne S (1991) Effects of a MAO-B inhibitor in the treatment of Alzheimer’s disease. Eur Neurol 31: 100–107

    Article  PubMed  CAS  Google Scholar 

  • Martignoni E, Bono G, Blandini F, Sinforiani E, Merlo P, Nappi G (1991) Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer’s type. Influence of treatment with 1-deprenyl. J Neural Transm [PD-Sect] 3: 15–25

    Article  CAS  Google Scholar 

  • Mattson M (1997) Central role of oxyradicals in the mechanism of amyloid β-peptide cytotoxicity. Alzheimer’s Dis Rev 2: 1–14

    CAS  Google Scholar 

  • Meydani M (1995) Vitamin E. Lancet 345: 170–174

    Article  PubMed  CAS  Google Scholar 

  • Monteverde A, Gnemmi P, Rossi F, Monteverde A (1990) Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clin Ther 12: 315–322

    PubMed  CAS  Google Scholar 

  • Münch G, Taneli Y, Schraven E, Schindler U, Schinzel R, Palm D, Riederer P (1994) The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylate. J Neural Transm [PD-Sect] 8: 193–208

    Article  Google Scholar 

  • Münch G, Simm A, Double KL, Riederer P (1996) Commentary: Oxidative stress and advanced glycation endproducts-parts of a vicious circle of neurodegeneration. Alzheimer’s Dis Rev 1: 71–74

    Google Scholar 

  • Nitta A, Murakami Y, Furukawa Y, Kawatsura W, Hayashi K, Yamada K, Hasegawa T, Nabeshima T (1994) Oral administration of idebenone induces nerve growth factor in the brain and improves learning and memory in basa forebrain-lesioned rats. Naunyn Schmiedebergs Arch Pharmacol 349: 410–407

    Article  Google Scholar 

  • Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328: 176–183

    Article  Google Scholar 

  • Parnetti L (1995) Clinical pharmacokinetics of drugs for Alzheimer’s disease. Clin Pharmacokinet 29: 110–129

    Article  PubMed  CAS  Google Scholar 

  • Parnetti L, Ambrosoli L, Abate G, Azzini C, Balestreri R, Bordin A, Crepaldi G, Christiani G, Cucinotta D (1995) Posatireline for the treatment of late onset Alzheimer’s disease: a double-blind multicentre study vs citicoline and ascorpic acid. Acta Neurol Scand 92: 135–140

    Article  PubMed  CAS  Google Scholar 

  • Peyser CE, Folstein M, Chase GA, Starkstein S, Brandt J, Cockrell JR, Bylsma F, Coyle JT, Mchugh PR, Folstein SE (1995) Trial of d-α-Tocopherol in Huntington’s disease. Am J Psychiatry 152: 1771–1775

    PubMed  CAS  Google Scholar 

  • Piccinin GL, Final G, Piccirilli M (1990) Neuropsychological effects of 1-deprenyl in Alzheimer’s type dementia. Clin Neuropharmacol 13: 147–163

    Article  PubMed  CAS  Google Scholar 

  • Rösler M, Retz W, Thome J, Riederer P (1998) Free radicals in Alzheimer’s dementia: currently available theraeutic strategies. J Neural Transm [Suppl] 53: 211–219

    Google Scholar 

  • Sano M, Ernesto C, Thomas R, Klauber M, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman C, Pfeifer E, Schneider L, Thal L (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 336: 1216–1222

    Article  PubMed  CAS  Google Scholar 

  • Schneider L, Pollo V, Zemansky M, Gleason R, Palmer R, Sloane B (1991) A pilot study of lowdose 1-deprenyl in Alzheimer’s disease. J Ger Psychiat Neurol 4: 143–148

    Article  CAS  Google Scholar 

  • Schneider L, Olin J, Pawluczyk S (1993) A double-blind crossover pilot study of 1-deprenyl (selegiline) combined with Cholinesterase inhibitor in Alzheimer’s disease. Am J Psychiatry 150: 321–323

    PubMed  CAS  Google Scholar 

  • Senin U, Parnetti L, Barbagallo-Sangiorgi G, Bartorelli L, Bocola V, Capurso A, Cuzzupoli M, Denaro M, Margliano V, Tammaro AE, Fioravanti M (1992) Idebenone in senile dementia of Alzheimer type: a multicentre study. Arch Gerontol Geriatr 15: 249–260

    Article  PubMed  CAS  Google Scholar 

  • Smith MA, Sayre L, Perry G (1996) Is Alzheimer’s a disease of oxidative stress? Alzheimer’s Dis Rev 1: 63–67

    CAS  Google Scholar 

  • Stevens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson J, Brown MJ (1996) Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347: 781–787

    Article  Google Scholar 

  • Sunderland T, Tariot PN, Cohen RM, Newhouse PA, Mellow AM, Mueller EA, Murphy DL (1987) Dose-dependent effects of deprenyl on CSF metabolites in patients with Alzheimer’s disease. Psychopharmacology 91: 293–296

    Article  PubMed  CAS  Google Scholar 

  • Suno M, Nagaoka A (1984) Inhibition of lipid peroxidation by a novel compound (CV-2619) in brain mitochondria and mode oc action of the inhibition. Biochem Biophys Commun 125: 1046–1052

    Article  CAS  Google Scholar 

  • Tariot P, Cohen R, Sunderland T, Newhouse P, Yount D, Mellow A, Weingartner H, Mueller E, Murphy D (1987a) L-deprenyl in Alzheimer’s disease. Arch Gen Psychiatry 44: 427–433

    Article  PubMed  CAS  Google Scholar 

  • Tariot P, Sunderland T, Weingartner H, Murphy D, Welkowitz J, Thompson K, Cohen R (1987b) Cognitive effects of 1-deprenyl in Alzheimer’s disease. Psychopharmacology 91: 489-95

    Article  PubMed  CAS  Google Scholar 

  • Thome J, Münch G, Müller R, Schinzel R, Kornhuber J, Blum-Degen D, Sitzmann L, Rösler M, Heidland A, Riederer P (1996) Advanced glycation endproducts—associated parameters in the blood of patients with Alzheimer’s disease. Life Sci 59: 679–685

    Article  PubMed  CAS  Google Scholar 

  • Thome J, Gsell W, Rösler M, Kornhuber J, Frölich L, Hashimoto E, Zielke B, Wiesbeck GA, Riederer P (1997) Oxidative-stress associated parameters (lactoferrin, superoxide dismutase) in serum of patients with Alzheimer’s disease. Life Sci 60: 13–19

    Article  PubMed  CAS  Google Scholar 

  • Weitbrecht WU, Jansen W (1986) Primär degenerative Demenz: Therapie mit Ginkgo-biloba-Extract. Fortschr Med 104: 199–202

    PubMed  CAS  Google Scholar 

  • Weyer G, Erzigkeit H, Hadler D, Kubicki S (1996) Efficacy and safety of idebenone in the longterm treatment of Alzheimer’s disease: a double-blind, placebo controlled multicentre study. Hum Psychopharmacol 11: 53–65

    Article  CAS  Google Scholar 

Download references

Authors
  1. M. Rösler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Retz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinische Neurochemie, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. Bezirkskrankenhaus Gabersee, Wasserburg/Inn, Bundesrepublik Deutschland

    Gerd Laux

  3. Wien, Österreich

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Wien

About this chapter

Cite this chapter

Rösler, M., Retz, W. (1999). Therapie von oxidativem Streß. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6400-6_71

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6400-6_71

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-7315-2

  • Online ISBN: 978-3-7091-6400-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation